文献速递心脑血管急症重症综合管理与镇静镇痛

降低缺血性卒中后残疾的电磁刺激治疗:EMAGINE随机临床试验

Electromagnetic Stimulation to Reduce Disability After Ischemic Stroke: The EMAGINE Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2025-10-01
一句话结论在亚急性缺血性卒中伴中重度残疾患者中,ENTF治疗安全,但90天mRS残疾改善较假刺激组未达统计学显著,mRS 0-1分达成率26.0% vs 10.0%(OR 2.99,95%CI 0.96-9.30,P=.05),作者认为可能对基线严重残疾者有益,需更高把握度试验确认。

EMAGINE是一项多中心、双盲、假刺激对照随机临床试验,在美国15家急性期和住院康复机构纳入卒中后4-21天、基线mRS 3-4分且上肢Fugl-Meyer评分10-45分的患者,随机接受主动或假ENTF刺激,并联合基于证据的功能性重复居家物理和作业训练,共45次每次1小时、卒中后90天内每周5次。计划样本150例,因前78例可评估者中期分析未达到有希望区域阈值而提前终止,实际入组100例(主动组50例、假刺激组50例)。主要终点为基线至90天mRS变化,主动组平均减少1.96(SD 0.12)vs 假刺激组1.72(SD 0.12),差异无统计学显著;mRS 0-1分达成12例(26.0%)vs 5例(10.0%),OR 2.99(95%CI 0.96-9.30,P=.05)。次要终点点估计均偏向主动组但未达统计学显著,未观察到ENTF设备相关严重不良事件。作者认为ENTF安全,虽组间差异未达统计学显著,但可能降低基线严重残疾患者的整体残疾,需更高把握度的确证性试验。

要点

  • 在卒中后4-21天、基线mRS 3-4分且上肢Fugl-Meyer评分10-45分的患者中,90天mRS平均减少主动组1.96 vs 假刺激组1.72,未达统计学显著。
  • 90天mRS 0-1分达成率主动组26.0% vs 假刺激组10.0%,OR 2.99(95%CI 0.96-9.30,P=.05),置信区间跨1。
  • 试验因前78例可评估者中期分析未达有希望区域阈值而提前终止,实际入组100例(主动组50例、假刺激组50例),计划样本150例。
  • 基线存在组间不平衡:主动组右侧半球卒中63.3% vs 假刺激组44.9%,严重上肢损伤63.3% vs 49.0%,小血管梗死28.6% vs 42.9%。
  • 未观察到ENTF设备相关严重不良事件;作者认为ENTF安全,结果需更高把握度的确证性试验确认。

适用人群与场景

  • 卒中后4至21天入组、基线mRS 3或4分(中度或中重度整体残疾)且上肢Fugl-Meyer评分10至45分的亚急性缺血性卒中患者。
  • 研究在美国15家急性期和住院康复机构开展,治疗为居家基于脑机接口的刺激设备联合功能性重复物理和作业训练。

诊断标准与关键阈值

  • 基线mRS评分3或4分定义为中度或中重度整体残疾。
  • 上肢Fugl-Meyer评分10至45分(分值越高上肢功能越好)。
  • 主要终点为基线至90天mRS变化,mRS评分范围0分(正常或无症状)至6分(死亡)。

处置流程与药物剂量

  • 主动或假ENTF刺激使用专有脑机接口刺激设备,联合基于证据的功能性重复居家物理和作业训练。
  • 治疗安排为45次每次1小时,卒中后90天内每周5次。

研究设计与关键结果

  • 多中心、双盲、假刺激对照随机临床试验,计划样本150例,因前78例可评估者中期分析未达到有希望区域阈值而提前终止,实际入组100例(主动组50例、假刺激组50例)。
  • 参与者平均年龄59.0(12.5)岁,男性66例(67.3%),卒中至首次ENTF治疗中位时间14(IQR 12-19)天。
  • 主要终点:90天mRS平均减少主动组1.96(SD 0.12)vs 假刺激组1.72(SD 0.12),差异无统计学显著;mRS 0-1分达成主动组12例(26.0%)vs 假刺激组5例(10.0%),OR 2.99(95%CI 0.96-9.30,P=.05)。
  • 次要终点点估计均偏向主动组,但预设分析中差异未达统计学显著。
  • 未观察到ENTF设备相关严重不良事件。
  • 基线不平衡:主动组vs假刺激组右侧半球卒中31/49(63.3%)vs 22/49(44.9%),肩外展手指伸展评分<5者31/49(63.3%)vs 24/49(49.0%),小血管梗死14/49(28.6%)vs 21/49(42.9%)。

证据类型、等级与局限

  • 证据类型:多中心、双盲、假刺激对照随机临床试验。
  • 试验提前终止,实际样本量100例(计划150例);作者结论指出结果需更高把握度的确证性试验确认。

对床旁实践的改变

  • 作者认为ENTF治疗安全,虽组间差异未达统计学显著,但可能降低基线严重残疾的缺血性卒中患者的整体残疾。
  • 作者结论指出这些结果需在更高把握度的ENTF确证性试验中确认。

指南或共识出处

  • EMAGINE随机临床试验(ClinicalTrials.gov标识NCT05044507)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Ischemic stroke remains a leading cause of disability worldwide. Preliminary studies have suggested that noninvasive, frequency-tuned, low-intensity electromagnetic network targeting field (ENTF) stimulation may have recovery benefit for patients with stroke.

OBJECTIVE: To evaluate the safety and effectiveness of ENTF therapy in reducing global disability among patients in the subacute ischemic stroke phase with moderate to severe disability and upper-extremity impairment.

DESIGN, SETTING, AND PARTICIPANTS: This multicenter, double-blind, sham-controlled, randomized clinical trial was conducted at 15 US-based acute care and inpatient rehabilitation facilities from December 2021 to November 2023. Participants were enrolled 4 to 21 days after a stroke and had a baseline modified Rankin Scale (mRS) score of 3 or 4 (moderate or moderately severe global disability) and Fugl-Meyer Assessment for Upper Extremity score of 10 to 45 (higher scores indicating better arm function). Target sample size was 150 participants. Participants were randomly allocated to receive either active or sham ENTF stimulation. Modified intention-to-treat approach was used in primary efficacy and safety analyses.

INTERVENTION: Participants allocated to the active or sham ENTF stimulation were treated with a proprietary brain-computer interface-based stimulation device paired with an evidence-based, functional, repetitive, home-based physical and occupational exercise regimen for 45 one-hour sessions, 5 times per week within the first 90 days after a stroke.

MAIN OUTCOMES AND MEASURES: The primary end point was change in global disability, assessed with the mRS (score range: 0 [indicating normal or no symptoms] to 6 [indicating death]), from baseline to day 90. Secondary end points were change from baseline to day 90 in upper-limb impairment, arm motor function, gait speed, hand function, and physical and functional limitations as well as day-90 health-related quality of life, each of which was assessed with a specific metric.

RESULTS: The trial was stopped early after enrollment of 100 participants (50 in active group, 50 in sham group) when a promising zone threshold was not attained at planned interim analysis of the first 78 evaluable participants. Participants had a mean age of 59.0 (12.5) years and included 66 males (67.3%). The median (IQR) time from stroke to first ENTF treatment was 14 (12-19) days. Study groups were similar in age, sex, and baseline mRS scores, but imbalances were noted with participants in the active, compared with the sham, group having more right-hemisphere strokes (31 of 49 [63.3%] vs 22 of 49 [44.9%]), more severe upper-extremity impairment (Shoulder Abduction Finger Extension score <5; 31 of 49 [63.3%] vs 24 of 49 [49.0%]), and fewer small-vessel infarcts (14 of 49 [28.6%] vs 21 of 49 [42.9%]). For the primary outcome, the mean (SD) disability reduction on mRS at day 90 was not statistically significantly higher in the active group than in the sham group (-1.96 [0.12] vs -1.72 [0.12]), including mRS score of 0 to 1 attained in 12 participants (26.0%) vs 5 participants (10.0%) (odds ratio, 2.99; 95% CI, 0.96-9.30; P = .05). Point estimates for secondary outcomes favored the active group, although the differences were not statistically significant, in the prespecified analysis. No ENTF device-related serious adverse events were noted.

CONCLUSION AND RELEVANCE: This trial found that ENTF therapy is safe. Although the difference between groups was not statistically significant, ENTF therapy may reduce global disability in patients with severe baseline disability after ischemic stroke. These results warrant confirmation in a higher powered pivotal trial of ENTF therapy.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT05044507.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Saver JL, Duncan PW, Stein J, et al. Electromagnetic Stimulation to Reduce Disability After Ischemic Stroke: The EMAGINE Randomized Clinical Trial. JAMA Netw Open. 2025. PMID: 41105410. doi:10.1001/jamanetworkopen.2025.37880

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。